Skip to main content
SpringerLink
Log in

5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions

  • Reviews
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The introduction of buspirone for the treatment of anxiety, together with the eventual suggestion of a mode of action involving the serotonin (5-HT)1A receptor subtype, has generated considerable research activity and renewed interest in the potential role of 5-HT in anxiety. The further identification of multiple 5-HT1 receptors, coupled with the possibility that these subtypes potentially are involved in discrete biobehavioral regulation and pathophysiological conditions, has greatly expanded the search for tools capable of probing these receptors and has raised hopes for a new generation of more specific compounds to treat other disorders associated with the 5-HT system such as depression, aggression, and sleep and eating disturbances. The involvement of 5-HT in anxiety has prompted a careful reevaluation of several traditional areas of research. This has included those methods used in the in vivo evaluation of drugs in preclinical animal test procedures used to assess potential anxiolytic activity, as well as the mechanisms associated with adaptive changes occurring during long-term drug administration. The proliferation of various procedures for studying the anxiolytic effects of 5-HT drugs has not always been accompanied by systematic behavioral and pharmacological validation. At the present time, this area of research is characterized by numerous inconsistent findings. Procedures that are objective and impartial to the behavioral effects of drugs provide distinct advantages for addressing some of these issues, as will the results from carefully controlled clinical studies. The main objective of this article is to provide an overview of the recent developments in research involving the 5-HT system and anxiety. The emphasis will be on the 5-HT1 receptor system and a review of the results in the predominant animal models used to evaluate these drugs, as well as an overview of the mechanisms currently believed to be responsible for the therapeutic activity of this class of compounds. Studies with the pigeon are reviewed, since this species appears distinctly sensitive to the anxiolytic-like effects of 5-HT1A drugs in conflict procedures. Although chronic administration of 5-HT1A drugs appears necessary for clinical anxiolytic and antidepressant activity, the most noteworthy neuropharmacological effects in animals seem to occur in 5-HT2 and, perhaps, 5-HT3 receptors which are downregulated. Studies summarizing the activity of drugs interacting with 5-HT1C/2 and 5-HT3 receptor sites are also discussed as they too may be involved in anxiety or the actions of anxiolytic drugs. The growing evidence suggesting an interaction between 5-HT receptor types, particularly between 5-HT1A and 5-HT1C/2 receptors, is reviewed, since drugs with these combined properties appear to be particularly efficacious in animal models of anxiety and warrant further detailed analyses. The development of drugs targeted specifically at multiple receptors may provide distinct therapeutic advantages for disorders such as anxiety and depression that appear to involve multiple neurotransmitter systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abou-Gharbia M, Moyer JA (1990) WY-50,324. Drugs Fut 15:1093–1904

    Google Scholar 

  • Acquas E, Carboni E, Garau L, Di Chiara G (1990) Blockade of acquisition of drug-conditioned place aversion by 5-HT3 antagonists. Psychopharmacology 100:459–463

    Google Scholar 

  • Arnt J, Hyttel J (1989) Facilitation of 8-OH-DPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161:45–51

    Google Scholar 

  • Awouters F, Niemegeers CJE, Megens AAHP, Janssen PAJ (1990) Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine. J Pharmacol Exp Ther 254:945–951

    Google Scholar 

  • Backus LI, Sharp T, Grahame-Smith DG (1990) Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol 100:793–799

    Google Scholar 

  • Barnes JM, Barnes NM, Costall B, Domeney AM, Johnson DN, Kelly ME, Munson HR, Naylor RJ, Young R (1990a) The differential activities of R(+)- and S(−)-zacopride as 5-HT3 receptor antagonists. Pharmacol Biochem Behav 37:717–727

    Google Scholar 

  • Barnes JM, Costall B, Coughlan J, Domeney AM, Gerrard PA, Kelly ME, Naylor R, Onaivi ES, Tomkins DM, Tyers MB (1990b) The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 35:955–962

    Google Scholar 

  • Barnes JM, Barnes NM, Cooper SJ (1992) Behavioural pharmacology of 5-HT3 receptor ligands. Neurosci Biobehav Rev 16:107–113

    Google Scholar 

  • Barrett JE (1991) Animal behavior models in the analysis and understanding of anxiolytic drugs acting at serotonin receptors. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser, Basel, pp 37–52

    Google Scholar 

  • Barrett JE (1992) Studies on the effects of 5-HT1A drugs in the pigeon. Drug Dev Res 26:299–317

    Google Scholar 

  • Barrett JE, Gleeson S (1991) Anxiolytic effects of 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. Wiley, New York, pp 59–105

    Google Scholar 

  • Barrett JE, Witkin, JM (1991) Buspirone in animal models of anxiety In: Tunnicliff G, Eison A, Taylor D (eds) Buspirone: mechanisms and clinical aspects. Academic Press, Orlando, pp 37–79

    Google Scholar 

  • Barrett JE, Zhang L (1991) Anticonflict and discriminative stimulus effects of the 5-HT1A compounds WY-47,846 and WY-48,723 and the mixed 5-HT1A agonist/5-HT2 antagonist WY-50,324 in pigeons. Drug Dev Res 24:179

    Google Scholar 

  • Berendsen HHG, Broekkamp CLE (1990) Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 101:667–673

    Google Scholar 

  • Blanchard DC, Blanchard RJ, Rodgers RJ (1991) Risk assessment and animal models of anxiety. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser, Basel, pp 117–134

    Google Scholar 

  • Boddeke HWGM, Fargin A, Raymond JR, Schoeffter P, Hoyer D (1992) Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells. Naunyn-Schmiedeberg's Arch Pharmacol 345:257–263

    Google Scholar 

  • Briley M, Chopin P, Moret C (1991) The role of serotonin in anxiety: Behavioural approaches. In: Briley M, File SE (eds) New concepts in anxiety. CRC Press, Boca Raton FL, pp 56–73

    Google Scholar 

  • Brocco MJ, Koek W, Degryse A-D, Colpaert FC (1990) Comparative studies on the anti-punishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon, Geller-Seifter and Vogel conflict procedures. Behav Pharmacol 1:403–418

    Google Scholar 

  • Ceulemans DLS, Hoppenbrouwers M-L, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18:303–305

    Google Scholar 

  • Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14–24

    Google Scholar 

  • Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. TIPS 8:383–388

    Google Scholar 

  • Colpaert FC, Koek W, Lehmann J, Rivet J-M, Lejeune F, Canton H, Bervoets K, Millan MJ, Laubie M, Lavielle G (1992) S 14506: a novel, potent, high-efficacy 5-HT1A agonist and potential anxiolytic agent. Drug Dev Res 26:21–48

    Google Scholar 

  • Costall B, Naylor B (1991) Anxiolytic effects of 5-HT3 antagonists in animals. In: Rodgers RJ, Cooper SJ (eds.) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. Wiley, Chichester, England, pp 133–157

    Google Scholar 

  • Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894

    Google Scholar 

  • Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ (1988) Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol 40:302–305

    Google Scholar 

  • Costall B, Jones BJ, Kelly E, Naylor RJ, Tomkins DM (1989) Exploration of mice in a black and white test box: Validation as a model of anxiety. Pharmacol Biochem Behav 32:777–785

    Google Scholar 

  • Cutler MG (1990) Behavioural effects in gerbils of the 5-HT3 receptor antagonists, BRL 43694 and ICS 205-930, under circumstances of high and low light intensity. Neuropharmacology 29:515–520

    Google Scholar 

  • Cutler MG (1991) An ethological study of the effects of buspirone and the 5-HT3 receptor antagonist, BRL 43694 (granisetron) on behaviour during social interactions in female and male mice. Neuropharmacology 30:299–306

    Google Scholar 

  • Cutler MG, Piper DC (1990) Chronic administration of the 5-HT3 receptor antagonist BRL 43694; effects on reflex epilepsy and social behaviour of the Mongolian gerbil. Psychopharmacology 101:244–249

    Google Scholar 

  • Darmani NR, Martin BR, Pandey U, Glennon RA (1990) Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav 36:901–906

    Google Scholar 

  • Deakin JFW, Guimaraes FS, Wang M, Hellewell J, Hensman R (1991) 5-HT mechanisms in human anxiety. In: Briley M, File SE (eds) New concepts in anxiety. CRC Press, Boca Raton FL, pp 74–93

    Google Scholar 

  • De Vry J, Glaser T, Schuurman T, Schreiber R, Traber J (1991) 5-HT1A receptors in anxiety. In: Briley M, File SE (eds) New concepts in anxiety. CRC Press, Boca Raton FL, pp 94–129

    Google Scholar 

  • Dunn RW, Carlezon Jr WA, Corbett, R (1991) Preclinical anxiolytic versus antipsychotic profiles of the 5-HT3 antagonists ondansetron, zacopride, 3α-tropanyl-1H-indole-3-carboxylic acid ester, and 1αH, 3α, 5αH-tropan-3-yl-3,5-dichlorobenzoate. Drug Dev Res 23:289–300

    Google Scholar 

  • Eison AS, Yocca FD (1985) Reduction in cortical 5-HT2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol 111:389–392

    Google Scholar 

  • Fabre LF (1990) Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 51:55–61

    Google Scholar 

  • File SE, Johnston AL (1989) Lack of effects of 5-HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. Psychopharmacology 99:248–251

    Google Scholar 

  • Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, Rickels K (1992) Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology 25:193–201

    Google Scholar 

  • Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE (1989) Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 250:809–824

    Google Scholar 

  • Glenn B, Green S, (1989) Anxiolytic profile of GR 38032F in the potentiated startle paradigm. Behav Pharmacol 1:91–94

    Google Scholar 

  • Glennon RA, Nissar AD, Martin BR (1991) Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. Life Sci 48:2493–2498

    Google Scholar 

  • Goudie AJ, Leathley MJ (1990) Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawl in rats. Eur J Pharmacol 185:179–186

    Google Scholar 

  • Grant KA, Barrett JE (1991) Blockade of the discriminative stimulus effects of ethanol with 5-HT3 receptor antagonists. Psychopharmacology 104:451–456

    Google Scholar 

  • Haefely W, Martin JR, Schoch P (1990) Novel anxiolytics that act as partial agonists at benzodiazepine receptors. TIPS 11:452–456

    Google Scholar 

  • Hamon M, Lanfumey L, El Mestikawy S, Boni C, Miquel M-M, Bolanos F, Schechter L, Gozlan H (1990) The main features of central 5-HT1 receptors. Psychopharmacology 3:349–360

    Google Scholar 

  • Harrington MA, Zhong P, Garlow SJ, Ciaranello RD (1992) Molecular biology of serotonin receptors. J Clin Psychiatry 53:10 (suppl) 8-27

    Google Scholar 

  • Hartig PR, Adham N, Zgombick J, Weinshank R, Branchek T (1992) Molecular biology of the 5-HT1 receptor subfamily. Drug Dev Res 26:215–224

    Google Scholar 

  • Haskins JT, Moyer JA, Andree TH, Muth EA, Abou-Gharbia M (1989) Preclinical profile of the pyrimidinylpiperazinyl imide compound WY47,846: a potential anxiolytic. Drug Dev Res 18:29–45

    Google Scholar 

  • Hensler JG, Gyula BK, Frazer A (1991) A quantitative autoradiographic study of serotonin1A receptor regulation. Effect of 5,7-dihydroxytrtyptamine and antidepressant treatments. Neuropsychopharmacology 4:131–144

    Google Scholar 

  • Higgins GA, Jones BJ, Oakley NR, Tyers MB (1991) Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology 104:545–551

    Google Scholar 

  • Howard JL, Pollard GT (1990) Effects of buspirone in the Geller-Seifter conflict test with incremental shock. Drug Dev Res 19:37–49

    Google Scholar 

  • Huang KN, Julius D (1991) Molecular characterization of three serotonin receptor subtypes. In: Peroutka S (ed) Serotonin receptor subtypes: basic and clinical aspects. Wiley-Liss, New York, pp 1–17

    Google Scholar 

  • Janssen, PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AHP, Meert TF (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693

    Google Scholar 

  • Johnston AL, File SE (1988) Effects of 5-HT3 antagonists in two animal tests of anxiety. Neurosci Lett Suppl 32:S44

    Google Scholar 

  • Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist. Br J Pharmacol 93:985–993

    Google Scholar 

  • Kidd E, Bouchelet de Vendegies I, Levy J-C, Hamon M, Gozlan H (1992) The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system. Eur J Pharmacol 211:133–136

    Google Scholar 

  • Kilfoil T, Michel A, Montgomery D, Whiting RL (1989) Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice. Neuropharmacology 28:901–905

    Google Scholar 

  • Knapp DJ, Pohorecky LA (1992) Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats. Pharmacol Biochem Behav 41:847–850

    Google Scholar 

  • Koek W, Jackson A, Colpaert FC (1992) Behavioral pharmacology of antagonists at 5-HT2/5-HT1C receptors. Neurosci Biobehav Rev 16:95–105

    Google Scholar 

  • Lecci A, Borsini F, Volterra G, Meli A (1990) Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology 101:255–261

    Google Scholar 

  • Lister RG (1990) Ethologically-based animal models of anxiety disorders. Pharmacol Ther 46:321–340

    Google Scholar 

  • Lucki I (1992) 5-HT1 receptors and behavior. Neurosci Biobehav Rev 16:83–93

    Google Scholar 

  • Lucki I, Wieland S (1990) 5-Hydroxytryptamine1A receptors and behavioral rersponses. Neuropsychopharmacology 3:481–493

    Google Scholar 

  • Meller E, Goldstein M, Bohmaker K (1990) Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharmacol 37:231–237

    Google Scholar 

  • Millan MJ, Canton H, Lavielle G (1992a) Targeting multiple serotonin receptors: Mixed 5-HT1A agonists/5-HT1C/2 antagonists as therapeutic agents. Drug News Perspect 7:397–406

    Google Scholar 

  • Millan MJ, Rivet J-M, Canton H, Lejeune F, Bervoets K, Brocco M, Gobert A, Lefebvre De Ladonchamps B, Le Marouille-Girardon S, Verriele L, Laubie M, Lavielle G (1992b) S 14671: A naphthylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors. J Pharmacol Exp Ther 262:451–463

    Google Scholar 

  • Mos J, van der Heyden J, Olivier B (1989) Behavioural effects of 5-HT3 antagonists in animal models for aggression, anxiety and psychosis. In: Bevan P, Cools A, Archer T (eds) Behavioural pharmacology of 5-HT. Lawrence Erlbaum, Hillsdale, NJ, pp 389–395

    Google Scholar 

  • Moser PC, Tricklebank MD, Middlemiss DN, Mir AK, Hibert MF, Fozard JR (1990) Characterization of MDL 7300EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam. Br J Pharmacol 1:57–67

    Google Scholar 

  • Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM (1989) Comparative anxiogenic, neuroendocrine, and other physiologic effects ofm-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 98:275–282

    Google Scholar 

  • Nanry KP, Howard L, Pollard GT (1991) Effects of buspirone and other anxiolytics on punished key-pecking in the pigeon. Drug Dev Res 24:269–276

    Google Scholar 

  • Nastiti K, Benton P, Brain PF, Haug M (1991) The effects of 5-HT receptor ligands on ultrasonic calling in mouse pups. Neurosci Biobehav Rev 15:483–487

    Google Scholar 

  • New JS (1990) The discovery and development of buspirone: a new approach to the treatment of anxiety. Med Res Rev 10:283–326

    Google Scholar 

  • Newman ME, Shapira B, Lerer B (1991) Regulation of 5-hydroxytryptamine1A receptor function in rat hippocampus by short- and long-term administration of 5-hydroxytryptamine1A agonists and antidepressants. J Pharmacol Exp Ther 260:16–20

    Google Scholar 

  • Nutt DJ (1991) Anxiety and its therapy: today and tomorrow. In: Briley M, File SE (eds) New concepts in anxiety. CRC Press, Boca Raton FL

    Google Scholar 

  • Olivier B, Tulp MTM, Mos J (1991) Serotonergic receptors in anxiety and aggression; evidence from animal pharmacology. Hum Psychopharmacol 6:S73–78

    Google Scholar 

  • Onaivi ES, Martin BR (1989) Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Prog Neuropsychopharmacol Bio Psychiatry 13:963–976

    Google Scholar 

  • Papp M (1988) Similar effects of diazepam and the 5-HT3 receptor antagonist ICS 205-930 on place aversion conditioning. Eur J Pharmacol 151:321–324

    Google Scholar 

  • Pecknold JC, Luthe L, Scott-Fleury M-H (1991) Platelet [3H]-paroxetine and [3H]-imipramine binding in zacopride-treated patients with generalized anxiety disorder: preliminary results. In: Briley M, File SE (eds) New concepts in anxiety. CRC Press, Boca Raton FL, pp 168–184

    Google Scholar 

  • Pinkus LM, Sarbin NS, Gordon JC, Munson Jr HR, (1990) Antagonism of [3H]-zacopride binding to 5-HT3 recognition sites by its (R) and (S) enantiomers. Eur J Pharmacol 179:231–235

    Google Scholar 

  • Pollard GT, Howard JL (1990) Effects of drugs on punished behavior: pre-clinical tests for anxiolytics. Pharmacol Ther 45:403–424

    Google Scholar 

  • Pollard GT, Howard JL (1991) Cork gnawing in the rat as a screening method for buspirone-like anxiolytics. Drug Dev Res 22:179–187

    Google Scholar 

  • Pollard GT, Nanry KP, Howard JL (1992) Effects of tandospirone in three behavioral tests for anxiolytics. Eur J Pharmacol 221:297–305

    Google Scholar 

  • Pranzatelli MR, Pluchino RS (1991) The relation of central 5-HT1A and 5-HT2 Receptors: low dose agonist-induced selective tolerance in the rat. Pharmacol Biochem Behav 39:407–413

    Google Scholar 

  • Radja F, Laporte A-M, Daval G, Vergé D, Gozlan H, Hamon M (1991) Autoradiography of serotonin receptor subtypes in the central nervous system. Neurochem Int 18:1–15

    Google Scholar 

  • Robinson DS, Gammans RE, Shrotiya RC, Jenkins SW, Andary JJ, Alms DR, Messina ME (1990) Clinical effects of 5-HT1A partial agonists, buspirone and gepirone in the treatment of depression. Clin Neuropharmacol 13:228–229

    Google Scholar 

  • Sanger DJ (1990) The effects of buspirone and related compounds on suppressed operant responding in rats. J Pharmacol Exp Ther 254:420–426

    Google Scholar 

  • Sanger DJ (1991) Animal models of anxiety and the screening and development of novel anxiolytic drugs. In: Boulton A, Baker G, Martin-Iverson M (eds) Neuromethods, animal models in psychiatry, II vol 19. Humana Press, Clifton New Jersey, pp 147–198

    Google Scholar 

  • Sanger DJ (1992) Increased rates of punished responding produced by buspirone-like compounds in rats. J Pharmacol Exp Ther 261:513–517

    Google Scholar 

  • Schechter LE, Bolanos FJ, Gozlan H, Lanfumey L, Haj-Dahmane S, Laporte A-M, Fattaccini C-M, Hamon M (1990) Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther 255:1335–1347

    Google Scholar 

  • Schreiber R, De Vry J (1993) 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action? Prog Neuropsychopharmacol Biol Psychiatry 17:87–104

    Google Scholar 

  • Sharp T (1991) Biochemical measurement of serotonergic neurotransmission in vivo: effect of antidepressant and anxiolytic treatments. In: Elliott JM, Heal DJ, Marsden CA (eds) Experimental approaches to anxiety and depression. Wiley, New York, pp 115–149

    Google Scholar 

  • Taylor DP, Hyslop DK (1991) Chronic administration of buspirone down-regulates 5-HT2 receptor binding sites. Drug Dev Res 24:93–105

    Google Scholar 

  • Taylor DP, Eison MS, Riblet LA, Vandermaelen CP (1985) Pharmacological and clinical effects of buspirone. Pharmacol Biochem Behav 23:687–694

    Google Scholar 

  • Toubas PL, Able KA, Cau W, Logan LG, Seale TW (1990) Latency to enter a mirrored chamber: a novel behavioral assay for anxiolytic agents. Pharmacol Biochem Behav 35:121–126

    Google Scholar 

  • Tunnicliff G (1991) Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 69:149–156

    Google Scholar 

  • Tyrer P (1991) Anxiety and depression. In: Elliott JM, Heal DJ, Marsden CA (eds) Experimental approaches to anxiety and depression. Wiley, New York, pp 9–23

    Google Scholar 

  • Waeber C, Pinkus LM, Palacios JM (1990) The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with a high affinity in rat brain. Eur J Pharmacol 181:283–287

    Google Scholar 

  • Wettstein, JG (1988) Behavioral effects of acute and chronic buspirone. Eur J Pharmacol 151:341–344

    Google Scholar 

  • Whitton P, Curzon G (1990) Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology 100:138–140

    Google Scholar 

  • Wilkinson LO, Dourish CT (1991) Serotonin and animal behavior. In: Peroutka SJ (ed) Serotonin receptor subtypes: basic and clinical aspects. Wiley-Liss, New York, pp 147–210

    Google Scholar 

  • Winslow JT, Insel TR (1991) Serotonergic modulation of the rat pup ultrasonic isolation call: studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists. Psychopharmacology 105:513–520

    Google Scholar 

  • Wojnicki FHE, Barrett JE (1993) Anticonflict effects of buspirone and chlordiazepoxide in pigeons under a concurrent schedule with punishment and a changeover response. Psychopharmacology 112:26–33

    Google Scholar 

  • Wright IK, Heaton M, Upton N, Marsden CA (1992) Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. Psychopharmacology 107:405–414

    Google Scholar 

  • Yocca FD (1990) Neurochemistry and neurophysiology of buspirone and gepirone: Interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol 10:6S-12S

    Google Scholar 

  • Yocca FD, Wright RN, Margraf RR, Eison AS (1990) 8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake response in rats. Pharmacol Biochem Behav 35:251–254

    Google Scholar 

  • Yocca FD, Iben L, Meller E (1992) Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Mol Pharmacol 41:1066–1072

    Google Scholar 

  • Young R, Johnson DN (1991) Anxiolytic-like activity of R(+)- and S(−)-zacopride in mice. Eur J Pharmacol 201:151–155

    Google Scholar 

  • Zifa E, Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401–457

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Nervous System Research Department, Medical Research Division, Lederle Laboratories, American Cyanamid Co., 10965, Pearl River, NY, USA

    James E. Barrett & Kimberly E. Vanover

Authors
  1. James E. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimberly E. Vanover
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barrett, J.E., Vanover, K.E. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology 112, 1–12 (1993). https://doi.org/10.1007/BF02247357

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02247357

Key words

Search

Navigation